BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17286282)

  • 1. Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
    Grunt TW; Tomek K; Wagner R; Puckmair K; Kainz B; Rünzler D; Gaiger A; Köhler G; Zielinski CC
    J Cell Physiol; 2007 Jun; 211(3):803-15. PubMed ID: 17286282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells.
    Grunt TW; Tomek K; Wagner R; Puckmair K; Zielinski CC
    Differentiation; 2007 Nov; 75(9):883-90. PubMed ID: 17608728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.
    Grunt TW; Puckmair K; Tomek K; Kainz B; Gaiger A
    Biochem Biophys Res Commun; 2005 Apr; 329(4):1253-9. PubMed ID: 15766561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells.
    Egeblad M; Mortensen OH; van Kempen LC; Jäättelä M
    Biochem Biophys Res Commun; 2001 Feb; 281(1):25-31. PubMed ID: 11178955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4.
    Hayashi K; Goodison S; Urquidi V; Tarin D; Lotan R; Tahara E
    Int J Oncol; 2003 Mar; 22(3):623-9. PubMed ID: 12579317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor transactivation by intracellular prostaglandin E2-activated prostaglandin E2 receptors. Role in retinoic acid receptor-β up-regulation.
    Fernández-Martínez AB; Lucio Cazaña FJ
    Biochim Biophys Acta; 2013 Sep; 1833(9):2029-38. PubMed ID: 23644172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells.
    Whang YM; Choi EJ; Seo JH; Kim JS; Yoo YD; Kim YH
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):543-55. PubMed ID: 15959780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression.
    Rosenauer A; Nervi C; Davison K; Lamph WW; Mader S; Miller WH
    Cancer Res; 1998 Nov; 58(22):5110-6. PubMed ID: 9823320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.
    Yamamoto M; Ito T; Shimizu T; Ishida T; Semba K; Watanabe S; Yamaguchi N; Inoue J
    Cancer Sci; 2010 Nov; 101(11):2391-7. PubMed ID: 20735436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells.
    Stefanska B; Rudnicka K; Bednarek A; Fabianowska-Majewska K
    Eur J Pharmacol; 2010 Jul; 638(1-3):47-53. PubMed ID: 20447390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
    Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
    Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing and re-expression of retinoic acid receptor beta2 in human melanoma.
    Fan J; Eastham L; Varney ME; Hall A; Adkins NL; Chetel L; Sollars VE; Georgel P; Niles RM
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):419-29. PubMed ID: 20374520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.
    Sirchia SM; Ferguson AT; Sironi E; Subramanyan S; Orlandi R; Sukumar S; Sacchi N
    Oncogene; 2000 Mar; 19(12):1556-63. PubMed ID: 10734315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.
    Petty WJ; Li N; Biddle A; Bounds R; Nitkin C; Ma Y; Dragnev KH; Freemantle SJ; Dmitrovsky E
    J Natl Cancer Inst; 2005 Nov; 97(22):1645-51. PubMed ID: 16288117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.